Long-Term Follow-up of Patients with Stage T1 High-Grade Transitional Cell Carcinoma Managed by Bacille Calmette-Guérin Immunotherapy

Urology

Volumn 69, Issue 1, 2007, Pages 78-82

  Margel, David ^a,b   Tal, Raanan ^a,b   Golan, Shai ^a,b   Kedar, Dani ^a,b   Engelstein, Dov ^a,b   Baniel, Jack ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33846475456     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.019     Document Type: Article

References (26)

1. Dutta S.C., Smith Jr. J.A., Shappell S.B., et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
2. Herr H.W., Jakse G., and Sheinfeld J. The T1 bladder tumor. Semin Urol 8 (1990) 254-261
3. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083-1086
4. Jakse G., Loidl W., Seeber G., et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?. J Urol 137 (1987) 39-43
5. Stockle M., Alken P., Engelmann U., et al. Radical cystectomy-often too late?. Eur Urol 13 (1987) 361-367
6. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
7. Eure G.R., Cundiff M.R., and Schellhammer P.F. Bacillus Calmette-Guérin therapy for high risk stage T1 superficial bladder cancer. J Urol 147 (1992) 376-379
8. Cookson M.S., and Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 148 (1992) 797-801
9. Pansadoro V., Emiliozzi P., Defidio L., et al. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 154 (1995) 2054-2058
10. Harland S.J. A second look at the pT1 G3 bladder tumour. Clin Oncol 17 (2005) 498-502
11. Baniel J., Grauss D., Engelstein D., et al. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52 (1998) 785-789
12. Patard J., Moudouni J.S., Saint F., et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58 (2001) 551-556
13. Pansadoro V., Emiliozzi P., de Paula F., et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. Urology 59 (2002) 227-231
14. Lebret T., Gaudez F., Herve J.M., et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34 (1998) 67-72
15. Hurle R., Losa A., Manzetti A., et al. Intravesical bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258-263
16. Peyromaure M., Guérin F., Amsellem-Ouazana D., et al. Intravesical bacillus Calmette-Guérin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 169 (2003) 2110-2112
17. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80 (1997) 762-765
18. Brake M., Loertzer H., Horsch R., et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin. J Urol 163 (2000) 1697-1701
19. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
20. Lamm D.L., DeHaven J.I., Shriver J., et al. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guérin versus intravesical bacillus Calmette-Guérin in superficial bladder cancer. J Urol 145 (1991) 738-740
21. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
22. Palou J., Laguna P., Millan-Rodriguez F., et al. Control group and maintenance treatment with bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488-1491
23. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
24. Manoharan M., and Soloway M.S. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 32 (2005) 133-145
25. Piaton E., Faynel J., Ruffion A., et al. p53 Immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression. Br J Cancer 93 2 (2005) 242-247
26. Yamana K., Bilim V., Hara N., et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 93 (2005) 544-547